Gottlieb: New types of drug products may require more medical-device style evaluations

Friday, September 8, 2017

With the coming influx of new types of medical technology like the recently approved gene therapy cancer treatment CAR-T, FDA needs to shift the way it evaluates safety and effectiveness, Commissioner Scott Gottlieb said in a speech Thursday.

Many new products like CAR-T are administered once but have long-term effects, making it hard to evaluate the risk-benefit ratio. As a result, Gottlieb said drug-type products may need to be evaluated in a way that is more similar to FDA's current evaluation process for medical devices, including more emphasis on the post-marketing stage, he said. Sarah points out that the medical device review process is generally shorter and less stringent than the drug approval process. (subscription required)

Media Contacts

Suzanne Ffolkes
VP of Communications

Anna Briseño
Director of Communications 

Without continued support for health research, many of the most promising young scientists, their ideas and a myriad of potentially life-changing scientific breakthroughs will vanish into oblivion.
Paul Marinec, PhD; University of California San Francisco